Propofol Manufacturer Ordered to Pay $365M in Nevada Hepatitis C Case, Plans Appeal
Teva, which was ordered to pay $365 million, said in a statement that the company clearly labeled the vials as single use and that aseptic procedures should be used at all times. The company believes there is enough evidence to warrant an appeal of the court's decision.
Baxter, which was ordered to pay $144 million, said it would also submit an appeal.
Mr. Chanin's case is the first of many to reach trial after a 2006 hepatitis C outbreak at Las Vegas endoscopy clinics. The $500 million award follows more than $5 million already awarded to Mr. Chanin and his wife by the same jury, according to the report.
Read the New York Times' report about the Las Vegas hepatitis C trial.
© Copyright ASC COMMUNICATIONS 2016. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- Adults who don't vaccinate cost $9B in 2015 from preventable diseases: 6 things to know
- Tenet shares jump 3.3%; Medical Facilities Corp. distributes 151st consecutive dividend payment & more — 5 key notes on ASC companies
- How physicians can leverage technology to succeed under MACRA — Insights from Elation Health's CEO
- St. Renatus launches 1st nasal spray dental anesthetic: 5 things to know
- Anesthesia Business Consultants releases fall 2016 newsletter: 3 notes